- Home
- WRLD vs PHAR Comparison
WRLD vs PHAR Comparison
Compare WRLD & PHAR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- WRLD
- PHAR
- Stock Information
- Founded
- WRLD 1962
- PHAR 1988
- Country
- WRLD United States
- PHAR Netherlands
- Employees
- WRLD N/A
- PHAR N/A
- Industry
- WRLD Finance: Consumer Services
- PHAR Biotechnology: Pharmaceutical Preparations
- Sector
- WRLD Finance
- PHAR Health Care
- Exchange
- WRLD Nasdaq
- PHAR Nasdaq
- Market Cap
- WRLD 656.7M
- PHAR 624.1M
- IPO Year
- WRLD 1991
- PHAR N/A
- Fundamental
- Price
- WRLD $141.16
- PHAR $8.86
- Analyst Decision
- WRLD
- PHAR Strong Buy
- Analyst Count
- WRLD 0
- PHAR 3
- Target Price
- WRLD N/A
- PHAR $27.00
- AVG Volume (30 Days)
- WRLD 29.6K
- PHAR 5.9K
- Earning Date
- WRLD 01-28-2025
- PHAR 03-13-2025
- Dividend Yield
- WRLD N/A
- PHAR N/A
- EPS Growth
- WRLD 29.62
- PHAR N/A
- EPS
- WRLD 14.42
- PHAR N/A
- Revenue
- WRLD $558,622,726.00
- PHAR $285,745,000.00
- Revenue This Year
- WRLD N/A
- PHAR $20.08
- Revenue Next Year
- WRLD $3.69
- PHAR $9.22
- P/E Ratio
- WRLD $9.70
- PHAR N/A
- Revenue Growth
- WRLD N/A
- PHAR 30.64
- 52 Week Low
- WRLD $101.85
- PHAR $6.65
- 52 Week High
- WRLD $161.63
- PHAR $12.20
- Technical
- Relative Strength Index (RSI)
- WRLD 61.78
- PHAR 48.50
- Support Level
- WRLD $136.02
- PHAR $8.50
- Resistance Level
- WRLD $154.97
- PHAR $9.50
- Average True Range (ATR)
- WRLD 4.18
- PHAR 0.56
- MACD
- WRLD -0.66
- PHAR 0.03
- Stochastic Oscillator
- WRLD 54.30
- PHAR 58.71
About WRLD World Acceptance Corporation
World Acceptance Corp operates a small-loan consumer finance business. The company offers short-term small installment loans, medium-term larger installment loans, related credit insurance and ancillary products and services to individuals. It also offers income tax return preparation services to its loan customers and other individuals.
About PHAR Pharming Group N.V.
Pharming Group is a global biopharmaceutical company dedicated to transforming the lives of patients with rare, debilitating, and life-threatening diseases. It is commercializing and developing an innovative portfolio of protein replacement therapies and precision medicines to serve the unserved rare disease patients. Its product includes Ruconest. The revenue is generated from the United States.